Last reviewed: June 30, 2026
Last updated: June 30, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Two medications dominate the weight loss conversation today: semaglutide (brand name Ozempic) and tirzepatide (brand name Mounjaro). While both activate GLP-1 receptor pathways in the brain and gut, tirzepatide adds a second mechanism by stimulating GIP receptors, creating a dual-action effect that some patients find more effective. This article breaks down how these therapies differ and what each one offers for sustainable weight management.
How Semaglutide and Tirzepatide Work Differently in Your Body
Semaglutide activates only the glucagon-like peptide-1 (GLP-1) receptor, a pathway that reduces hunger signals, slows stomach emptying, and increases feelings of fullness. This single-receptor approach has proven effective for weight loss, with clinical trials showing average reductions of 10–15% of body weight over 68 weeks. Semaglutide also improves blood sugar control and cardiovascular markers in many patients.
Tirzepatide engages both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously—a dual-receptor strategy sometimes called a GIP/GLP-1 agonist. By targeting two hunger and metabolism pathways at once, tirzepatide may produce stronger appetite suppression and more consistent weight loss. The SURMOUNT clinical trials showed tirzepatide users lost up to 22% of baseline body weight, exceeding single-receptor semaglutide outcomes in head-to-head comparisons.
Clinical Trial Results: Weight Loss Outcomes You Should Know
Semaglutide's efficacy is well-established through the SUSTAIN and SELECT trial series. Patients receiving semaglutide lost between 10–15% of body weight when combined with lifestyle changes, with some studies showing weight reductions up to 17% at higher doses. These results held steady for up to 2 years in extension trials, indicating sustained benefit with continued use.
Tirzepatide demonstrated more dramatic results in the SURMOUNT trials, where participants achieved 20–22% weight loss reductions at the highest doses. Importantly, more tirzepatide users reached clinically significant milestones (≥20% weight loss) compared to semaglutide users in the same study. Tirzepatide also showed additional metabolic benefits, including improved insulin sensitivity and reduced inflammatory markers in some patient subgroups.
Side Effects and Tolerability: What Patients Experience
Both medications share common GLP-1 side effects: nausea (especially during dose escalation), constipation, and mild gastrointestinal discomfort. These effects typically diminish after 2–3 weeks as the body adapts. Semaglutide's side effect profile is well-characterized, with nausea affecting 30–40% of users initially and severe cases resolving in most people within the first month.
Tirzepatide carries a similar tolerability profile but may produce slightly more initial gastrointestinal effects due to its dual-receptor activation. Some patients report stronger nausea during the first 2 weeks, though this usually resolves with continued use. Long-term safety monitoring across multiple cohorts has not revealed unexpected adverse events with either medication when used as directed by a healthcare provider.
Choosing Between Semaglutide and Tirzepatide: What Matters Most
Your choice between these medications depends on your weight loss goals, tolerance for side effects, and personal health history. Semaglutide may be ideal if you prefer a well-established therapy with decades of safety data (it was originally approved for diabetes in 2008) or if you experience significant nausea with other compounds. Tirzepatide suits patients seeking maximum weight loss potential and who can tolerate the initial adjustment period.
The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more weight loss: semaglutide or tirzepatide?
Tirzepatide typically produces greater weight loss, with clinical trials showing 20–22% reductions compared to semaglutide's 10–17% range. However, individual results vary significantly based on genetics, lifestyle, and adherence. The Precision Peptide Genetic Test helps identify which mechanism your body responds to most effectively.
Is tirzepatide safer than semaglutide?
Both medications have strong safety profiles when prescribed by qualified providers. Semaglutide has longer real-world use data, while tirzepatide shows comparable safety in clinical trials. Side effects are similar between the two, with nausea and constipation being most common and typically temporary.
Can I switch from semaglutide to tirzepatide if the first one doesn't work?
Yes, switching between these medications is medically sound if you're not achieving your weight loss goals or experiencing intolerable side effects. PlexusDx members can discuss medication changes with their clinical team, and the transition typically involves a short washout period before starting the new compound.
How much do compounded semaglutide and tirzepatide cost at PlexusDx?
PlexusDx compounded semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan) and compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan). Neither price increases with dose escalation—your dose may go up, but your price won't. All medications are HSA/FSA eligible and available to patients in all 50 states without insurance.
What does the Precision Peptide Genetic Test tell me about semaglutide vs. tirzepatide?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Should Ozempic Be Taken with Food?
Navigating Zepbound Dosing: What Is the Next Dose After 10 mg on Your Weight Loss Journey?